IOLCP to invest Rs 495 crore in three manufacturing expansions

Capex & Operations View source PDF Explain this filing

IOLCP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.4%Reaction day

₹210.65

prior close

₹207.80

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.2%-0.2% vs market

Pharmaceuticals peers, median of 174sector-0.2%-0.2% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.3

10m

+0.7

15m

+0.9

30m

+0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.4-0.2-0.2-0.2-0.2

Next day

+0.6-0.3+1.0-0.7+1.4

-7.4-0.2-7.2-0.7-6.7

-13.6-3.5-10.1-2.0-11.5

-6.5-3.6-2.9-2.4-4.1

-6.2-2.8-3.4-2.3-3.9

-4.0-1.4-2.6-0.8-3.3

15d

-0.1-3.0+2.9-2.3+2.2

-4.6-4.4-0.2-5.1+0.5

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

IOLCP plans to raise Ibuprofen capacity from 12,000 to 18,000 MT annually by December 2027, requiring about Rs 350 crore. It has also installed a 1,500 million-tablet formulation facility at a cost of Rs 110 crore, expected to begin commercial operations in Q3 FY2027, and will spend Rs 35 crore on a specialty chemicals facility under a long-term tolling agreement. All projects are funded through internal accruals.

Likely market impact

The investments could expand revenue and customer reach, but execution, commercialization delays and higher spending may pressure near-term returns.